The natural products novobiocin and derrubone have both demonstrated Hsp90 inhibition and structure-activity relationships have been established for each scaffold. Given these compounds share several key structural features, we hypothesized that incorporation of elements from each could provide insight to structural features important for Hsp90 inhibition. Thus, chimeric analogues of novobiocin and derrubone were constructed and evaluated. These studies confirmed that the functionality present at the 3-position of the isoflavone plays a critical role in determining Hsp90 inhibition and suggests that the bicyclic ring system present in both novobiocin and derrubone do not share similar modes of binding.
Introduction
In the past decade, the 90 kDa heat shock proteins (Hsp90) have garnered interest as a therapeutic target for the treatment of several human pathologies, including cancer. 1-6 As a molecular chaperone, Hsp90 is responsible for the conformational maturation and maintenance of more than 100 cellular proteins. 7 , 8 Hsp90 substrates function in a wide variety of cellular processes, including receptors, transcription factors, and protein kinase signaling pathways. [9] [10] [11] [12] [13] [14] Although many of these individual enzymes/proteins are individually sought-after anticancer targets, 15 inhibition of Hsp90 affords simultaneous degradation of multiple clients through utilization of the ubiquitin-proteasome pathway. 1, 11, [16] [17] [18] [19] Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. 16 In addition, studies have revealed that Hsp90 inhibitors accumulate in tumor cells more effectively than normal tissue, leading to differential selectivities of >200 fold. 20, 21 Coupled with the observation that Hsp90 is overexpressed in a variety of human malignancies, the development of Hsp90 inhibitors has become an attractive chemotherapeutic approach.
Novobiocin (1, Figure 1 ) is an ATP mimic that elicits antimicrobial activity through competitive inhibition of DNA Gyrase B's ATP-binding site. Neckers and co-workers hypothesized that novobiocin may also be capable of binding Hsp90, which binds nucleotides in a similar bent conformation as DNA Gyrase B. Subsequent studies demonstrated that novobiocin binds to a novel site within the C-terminus of Hsp90,22 -24 exhibits anti-tumor activity (~700 μM, SkBr3 cells), and induces concentration-dependent degradation of Hsp90 client proteins. 22 Several synthetic analogs of novobiocin have been prepared in an attempt to improve upon the relatively-poor activity manifested by the natural product. One such compound, A4, induced the expression of Hsp90 at 10 3 −10 4 lower concentration than that required for client protein degradation and exhibited potent neuroprotective effects, but completely lacked anti-proliferative activity. 25 In contrast, the A4-dimer displayed antiproliferative activity, implicating the benzamide side chain as a key moiety for conversion of a non-toxic compound into an anti-cancer agent. 26 In 2008, Burlison and co-workers described the first structure-activity relationships (SAR) for monomeric novobiocin analogs that exhibit anti-proliferative activity. 27 These studies demonstrated the importance of the 3-benzamide functionality for exhibiting antitumor activity and explored structural requirements of the benzamide sidechain. Further elucidation of the anti-proliferative SAR for the novobiocin scaffold were provided by the construction of analogs that contained variations of the coumarin ring system. 28 Coumarins bearing substituents at the 5-, 6-, and 8-positions were found to possess positional and functional requirements that attenuate anti-proliferative activity, while analogs with quinoline and naphthalene functionalities suggested the coumarin lactone is not required. Together, these results supported ongoing investigations aimed at identifying alternative ring systems to bridge the benzamide and noviose moieties.
The prenylated isoflavone, derrubone (2, Figure 2 ), was originally isolated from Derris robusta in 1969. 29 In 2007, a high-throughput screen identified 2 as a low micromolar inhibitor of Hsp90. 30 Soon after, a library of derrubone analogues was prepared and evaluated for antiproliferation activity. 31 Analogues exhibiting modest improvements in activity over the natural product were identified and found to induce concentration-dependent degradation of Hsp90 client proteins. Preliminary structure-activity trends demonstrated the importance of the 6-prenyl and 3-aryl sidechains for manifesting improved antiproliferative activity. However, no further understanding was gained towards elucidating derrubone's mode of Hsp90 inhibition, either through interaction with the N-terminus, the C-terminus, or an alternative mechanism of action.
Prior knowledge of SAR exhibited by novobiocin and derrubone analogues suggested these two seemingly-diverse scaffolds may share common structural features ( Figure 3 ). For example, both molecules contain an electron-deficient core in the form of an isoflavone or coumarin bicyclic ring system (highlighted in red) that are functionalized at the 3-and 7-positions with aryl-containing or hydroxyl functionalities, respectively. Furthermore, novobiocin analogues with alternative bicyclic ring systems in lieu of the coumarin were shown to retain Hsp90 inhibitory activity for novobiocin-derived C-terminal inhibitors. 28 In addition, previous studies on the novobiocin scaffold demonstrated that 6-and 8-alkyl groups were welltolerated and can afford increased antitumor activity (eg. 3). 27, 28, 32 Similarly, 6-or 8-prenyl groups also appear essential for derrubone analogues to exert anti-proliferative activity and Hsp90 inhibition. 31 These observations, along with the fact that no co-crystal structure of an inhibitor bound to the Hsp90 C-terminus exists, led us to question whether these molecules exert their activities through binding the same region of Hsp90. We hypothesized that the bicyclic motif of 1 and 2 were analogous and that incorporation of elements from both molecular libraries would provide insight into how structural features impact the mode and capacity of Hsp90 inhibition. The design, synthesis and evaluation of such chimeric molecules are described within this article.
Results and Discussion

Design of novobiocin-derrubone chimeras
To test our hypothesis, we set out to prepare a library of novobiocin and derrubone chimeric analogues ( Figure 4 ). This panel of analogues was unified by the isoflavone ring system that would differentially impart functionalities common to either the novobiocin or derrubone scaffold at the 3-, 5-, 6-, 7-, and 8-positions. In particular, key functionalities included the 3-benzamide or 3-acetamide, 8-methyl, and 7-functionalities identified from previouslydescribed novobiocin libraries27 , 28 ,32 and the 3-(3,4-methylenedioxy)phenyl, 5-hydroxyl, and 6-prenyl functionalities from the reported derrubone library. 31 In addition, the panel included a smaller subset of 2-amidoflavone analogues (5) to compare and contrast with the corresponding 3-amido-isoflavones. Isoflavone analogues were grouped into two basic structural categories; 3-amido-isoflavones (6) and 3-(3,4-methylenedioxy)phenyl-isoflavones (7).
As shown in Scheme 1, the derivatives were prepared in modular fashion through sequential coupling of noviose and acylation of the 3-amino-7-hydroxy-(iso)flavones (9) . We envisioned that the trichloroacetimidate of noviose carbonate (8) could be coupled with 3-amino-6-hydroxyflavones or 3-amino-7-hydroxyisoflavones in a manner similar to that previously described in our group. 33 Selection of the biaryl acid and acetamide was based upon previously obtained SAR for the benzamide side chain, which is known to bifurcate antitumor from neuroprotective activity, respectively. 25,27
Syntheses of 2-amido-flavone analogues
Novobiocin analogues that contain a flavone ring system in lieu of the coumarin were constructed to assess the impact of alternative ring systems for Hsp90 inhibition. Benzyl protection of the 5′-phenol of 11 provided 12 (Scheme 2). 34 Reaction of 12 with N,Ndimethylformamide dimethyl acetal afforded an enamine intermediate, which was condensed with hydroxylamine-hydrochloride to give isoxazole, 13. 35 Under thermal and basic conditions, 13 was converted to the 3-aminoflavone, 14. Acylation of aniline 14 provided amides 15a-b in excellent yield, 36 which upon hydrogenolysis, yielded phenols 16a-b as common intermediates. 37 Acylation of the 7-hydroxyl functionality afforded 17a-b. 36 Phenols 16a-b were reacted with the trichloroacetimide of noviose carbonate (8) in the presence of boron trifluoride etherate to provide noviosylated intermediates that, after carbonate removal, gave analogues 18a-b. 33 Selective deprotection of the carbonate intermediates presented an unexpected challenge as hydrolysis of the amide was also observed, likely a result of the functionality's vinylogous imide-like properties.
Syntheses of 3-amido-isoflavone analogues
Similarly, 3-amido-isoflavone analogues were constructed as complementary, regioisomeric variants of chromone-containing chimeric Hsp90 inhibitors. The two-step Hoesch condensation of 20 with appropriate resorcinols or phloroglucinols (21) followed by imine hydrolysis afforded aryl ketones 22a-c in high yield (Scheme 3). 31, 38 Notably, the phthalimide functionality proved more useful than simply a nitrogen protecting group, as poor phthalide solubility provided a handle to aid crystallization of subsequent intermediates. Cyclization of intermediates 22a-c to isoflavones 23a-c was performed using Bischler-Napieralski conditions as previously described. 31 Interestingly, cyclization of phloroglucinol-containing analogue 22c was accomplished in 48 h, while 4-keto-resorcinols 22a-b required 120 h. Presumably, this difference resulted from hydrogen bonding interactions between the orthophenol and ketone, precluding rotation to the required conformation for enamine displacement. Phthalide deprotection of 23a-c under thermal and acidic conditions 39,40 provided 3-aminoisoflavone intermediates that were difficult to separate from the resulting ortho-phthalic acid. Consequently, a one-pot, three-step deprotection, acylation, and hydrolysis procedure was employed to convert 3-phthalamido intermediates 23a-c into 3-amido analogues 24a-f in moderate yield. Acylation of intermediates 24a-f afforded 7-acetoxy analogues, 25a-f. 36 Novioslyation and deprotection of 24a-f as previously described provided analogues 26a-f. 33 
Syntheses of 3-(3,4-methylenedioxy)phenyl-isoflavone analogues
Analogues based on the 3-aryl-isoflavone core of derrubone were constructed to determine whether inclusion of 5-, 6-, 7-, and 8-functionalities of derrubone and/or novobiocin impart increased Hsp90 inhibitory activitiy. Reaction of resorcinols 27a-b with (3,4-methylenedioxyphenyl)acetonitrile under Hoesch conditions, followed by hydrolysis, afforded 2-keto-resorcinols 29a-b, which were cyclized to isoflavones 30a-b using the BischlerNapieralski protocol (Scheme 4). 31, 38, 41 Together with 30c ,31 these isoflavones served as scaffolds for further analogue construction. Acylation of the 7-phenol in 30a-c afforded 31a-c. 36 Similarly, noviosylation of 30a-c and subsequent carbonate hydrolysis provided 7-glycosylated analogues 32a-c. 33 
Syntheses of 5-deoxy-derrubone analogues
Starting with 5-deoxy-isoflavones 30a-b, allylation of the 7-phenol afforded 33a-b in moderate yields (Scheme 5). 36 Claisen rearrangement of 33a-b under thermal conditions provided C-allyl analogues 34a-c. 32 When 33a was reacted, formation of 8-allyl 34c was preferred versus 6-allyl 34a as previously described, although both compounds could be produced via this process. 31 We hypothesized that inclusion of an 8-methyl functionality in 33b would serve a dual purpose in simultaneously providing the ~10-fold increased Hsp90 inhibitory activity demonstrated by 8-methylnovobiocin analogues 27, 28 and preventing formation of the thermodynamically-preferred, yet ultimately undesired, 8-allyl Claisen product. Protection of the phenols of 34a-34c as acetates yielded 7-acetoxy 35a-c ,31 which were subjected to olefin cross-metathesis with 2-methyl-2-butene using the second generation Grubbs' catalyst to afford prenylated compounds 36a-c. 31 Removal of the acetate protecting groups provided 5-deoxy derrubone analogs, 37a-c. 31 
Biological evaluation of flavone and isoflavone analogues
Upon construction of the novobiocin-derrubone chimeric library, the compounds were evaluated for antiproliferative activity against SkBr3 (estrogen receptor negative, Her2 overexpressing breast cancer cells) and MCF-7 (estrogen receptor positive breast cancer cells). As shown in Tables 1-2, all 2-acetamido-flavones and 3-acetamido-isoflavones (R 3 = CH 3 ) were inactive, with the sole exception of 25e, which manifested modest anti-proliferative activity (93.7 ± 6.5 μM) against MCF-7 cells. These results are unsurprising and support previous observations that A4 and other related 3-acetamidocoumarins do not affect cell growth. 25 In contrast, all but one biaryl benzamide-containing analogue (Tables 1-2, R 3 = biaryl) exhibited anti-proliferative activity ranging from ~3-50 μM against both cell lines. The 6-hydroxyflavone, 16b, and 7-hydroxyisoflavones, 24b, 24d, and 24f, exhibited between 1.9-9-fold decreased activity against SkBr3 cells. Analogous 7-acetoxy analogues 25b, 25d, and 25f did not demonstrate a large disparity in activities against MCF-7 and SkBr3 cells as their phenolic counterparts. The sole exception to this trend was 17b, which was completely inactive against both cell lines for reasons that remain unclear. By comparison, 7-noviosylated cogeners (R 5 = noviose) were less active than 7-hydroxy and 7-acetoxy analogues but demonstrated equivalent potency against both cell lines. This observation supports the notion that 26b, 26d, and 26f induce their activity through similar modes of action against both MCF-7 and SkBr3 cells, a feature typically observed for other novobiocin-derived Hsp90 inhibitors. 27, 28, 32 Unfortunately, in comparison to previously-described coumarin-containing analogues 27 , both the 2-amidoflavone and 3-amidoisoflavone ring systems demonstrated decreased antiproliferative activity. In comparison to the analogous 8-methylcoumarin-containing analogue, 18b, 25f, and 26d manifested between 0-6-fold decreased activities against MCF-7 and SkBr3 cell lines. Interestingly, most analogues containing the 5-hydroxyl exhibited similar activities as analogous 5-proteo derivatives, suggesting that this functionality neither increases nor decreases activity. In contrast to trends observed in coumarin-containing analogues, 27, 28 inclusion of the 8-methyl functionality to the isoflavone derivatives garnered a more modest 1.8-2.0-fold increase in antiproliferative activity for 7-hydroxy and 7-acetoxy derivatives and a 1.6-2.0-fold decrease in activity for 7-noviosylated products.
As shown in Table 3 , 3-(3,4-methylenedioxy)phenyl-isoflavone analogues with similarity to the derrubone scaffold demonstrated interesting trends in antiproliferation activity. In contrast to 3-amido analogues, those lacking either 7-noviose or prenyl functionalities were inactive against both cell lines, an observation supportive of previously-described trends. 31 Detectable antiproliferation activity was only observed for analogues bearing either a 7-noviose, 6-prenyl, or 8-prenyl functionality. The 7-noviosylated analogues 32a-b manifested IC 50 s between 9-21 μM. For reasons that remain unclear, 32c was completely inactive. In contrast, prenylated derivatives, 37a-c, exhibited activities ranging from 13 μM to greater than 100 μM. Replacement of 7-noviose (32a) with either a 6-(37a) or 8-prenyl (37c) functionality appeared to induce differential properties against these two cell lines.
Comparing the antiproliferation activities of 37a-c to those observed for 2 and other previously-disclosed derrubone analogues 31 provides insight into the role of the 5-hydroxyl and 8-methyl functionalities. While the data suggests that removal of the 5-hydroxyl functionality does not impact anti-proliferation activity, its inclusion is useful for selectively installing the 6-prenyl functionality in derrubone analogues. 31 We had hoped that inclusion of an 8-methyl (37b) would simultaneously provide enhanced activity and selectivity during the Claisen rearrangement. While incorporation of an 8-methyl fulfilled the latter objective, such analogues demonstrated nearly 4-fold decreased activity.
Some of the more intriguing structure-activity trends were observed through comparison of 3-biarylbenzamide isoflavone analogues and 3-(3,4-methylenedioxy)phenyl isoflavone derivatives. The 7-hydroxy and 7-acetoxy isoflavone analogues with the 3-biaryl amide were collectively the most potent compounds in the library, while corresponding analogues containing the 3-(3,4-methylenedioxy)phenyl sidechain were inactive. On its own, this observation implicates the essential nature of the 3-benzamide sidechain for manifestation of anti-proliferation activity. However, the same trend was not evident when comparing the 7-noviosylated derivatives, as 3-(3,4-methyelendioxy)phenyl-containing analogues 32a-b were between 1.6-2.8-fold more active than 3-benzamide analogues 26b and 26d. Together, these trends indicate that the relationship between inclusion of the 3-functionality and antiproliferation activity is complex.
To provide additional support that the anti-proliferation activities of this library of analogues results from Hsp90 inhibition, analogues 26b and 37c were evaluated for their ability to induce degradation of Hsp90-dependent client proteins. As shown in Figure 5 , analogues 26b and 37c both induced concentration-dependent degradation of Hsp90 client proteins Her2 and cRaf. β-Actin, a non-Hsp90-dependent protein, was not affected by these analogues indicating selective degradation of Hsp90-dependent clients. The antiproliferative activities (26b, IC 50 = 25.2 μM; 37c, IC 50 = 39.1 μM) correlate well with the concentrations needed to induce Hsp90 client protein degradation, thereby linking Hsp90 inhibition directly to cell viability. None of these analogues induce the concentration-dependent increase in Hsp90 levels correlating to activation of the heat shock response, a feature consistent with other C-terminal Hsp90 inhibitors. A summary of structure-activity trends for flavone and isoflavone chimeras of novobiocin and derrubone are depicted in Figure 6 .
Conclusions
Although many of the chimeric analogues of novobiocin and derrubone exhibit antiproliferative activities, differences observed in structure-activity trends do not support our original hypothesis that the isoflavone ring of derrubone is analogous to the coumarin ring system present in the novobiocin scaffold. However, the identity of the functionality at the 3-position appears to play a critical role in determining the potency and mode of antiproliferative activity observed for both scaffolds. The 3-acetamide analogues were found to be non-toxic and may represent scaffolds that exhibit neuroprotection activity similar to A4, while 3-biarylbenzamide derivatives (eg. 26b) display moderate antiproliferation and downregulation of Hsp90 client proteins. Biarylbenzamide analogues containing a hydroxyl (16b) or acetoxy (25d) substituent in lieu of the typical noviose sugar exert antiproliferative effects more readily than the corresponding noviosylated derivatives. Isoflavone analogues containing the 3-aryl sidechain of derrubone only manifest antiproliferation activity when noviosylated (32a) or prenylated (37a).
Experimental
1-(5-(Benzyloxy)-2-hydroxyphenyl)ethanone (12)
Potassium carbonate (1.81 g, 13.09 mmol) and benzyl bromide (1.56 mL, 2.24 g, 13.12 mmol) were added in sequence to 2′,5′-dihydroxyacetophenone (2.00 g, 13.15 mmol) in acetone (41.0 mL) and the solution was then then heated to reflux for 48 h. After cooling to rt, the reaction was diluted with saturated aqueous NaHCO 3 solution (50 mL) and extracted with EtOAc (3 × 250 mL). The combined organic layers were washed with saturated aqueous NaCl solution (500 mL), dried (Na 2 SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO 2 , 5:1 Hexanes:EtOAc) to give 12 as a yellow amorphous solid (2.92 g, 92%): 1 H NMR (CDCl 3 , 500 MHz) δ 11.87 (s, 1H), 7.47-7.38 (m, 4H), 7.30 (m, 1H), 7.26 (d, J = 3.0 Hz, 1H), 7.19 (dd, J = 9.1, 3.0 Hz, 1H), 6.93 (d, J = 9.1 Hz, 1H), 5.06 (s, 2H), 2.59 (s, 3H).
4-(Benzyloxy)-2-(isoxazol-5-yl)phenol (13)
A suspension of 12 (5.05 g, 20.82 mmol) in N,N-dimethylformamide dimethyl acetal (40.8 mL) was then heated to 90° C for 2 h. After cooling to rt, the yellow precipitate was collected by filtration, washed with cold hexanes, and used without further purification.
Hydroxylamine hydrochloride (1.76 g, 25.29 mmol) was added to a solution of the enamine (20.82 mmol) in EtOH (245 mL) and the solution was then heated to reflux for 1 h. After cooling to rt, the solvent was concentrated, the residue was washed with water (200 mL), the solid was collected by filtration, redissolved in hot EtOAc (400 mL), filtered, and concentrated. Recrystallization from EtOAc:Hexanes gave 13 as a near-colorless amorphous solid (4.00 g, 72% over two steps): 1 H NMR (DMSO-d 6 , 500 MHz) δ 10.17 (brs, 1H), 8 
2-Amino-6-(benzyloxy)-4H-chromen-4-one (14)
Triethylamine (2.30 mL, 1.67 g, 16.50 mmol) was added to 13 (2.24 g, 8.38 mmol) in anhydrous N,N-dimethylformamide (93.0 mL) and the solution was then heated to 140-150° C for 18 h. After cooling to rt, the solvent was concentrated, the residue was suspended in water (200 mL), and the resulting solid was collected by filtration through celite. The solid was eluted with hot MeOH, the solvent was concentrated, cold Et 2 O (100 mL) was added, and the solid collected by filtration to give 14 as a yellow-orange amorphous solid (2.20 g, 57%): 1 H NMR (DMSO- 
N-(6-(Benzyloxy)-4-oxo-4H-chromen-2-yl)acetamide (15a)
4-(Dimethylamino)pyridine (346 mg, 2.83 mmol) was added to a suspension of 14 (490 mg, 1.83 mmol) in anhydrous acetonitrile (13.0 mL) at rt. After 3 h, acetyl chloride (675 μL, 745 mg, 9.49 mmol) was added and the solution was then heated to reflux for 18 h. After cooling to rt, water (100 mL) was added and the precipitate was collected by filtration and washed with cold Et 2 O (100 mL) to give 15a as a colorless amorphous solid (495 mg, 87%): 1 H NMR (DMSO-d 6 , 500 MHz) δ 11.24 (brs, 1H), 7.50 (d, J = 9.1 Hz, 1H), 7. 
N-(6-(Benzyloxy)-4-oxo-4H-chromen-2-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (15b)
4-(Dimethylamino)pyridine (346 mg, 2.83 mmol) was added to a suspension of 14 (500 mg, 1.87 mmol) in anhydrous acetonitrile (10.0 mL) at rt. After 3 h, freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride 28 (1.02 g, 3.67 mmol) in anhydrous acetonitrile (3.0 mL) was added and the solution was then heated to reflux for 18 h. After cooling to rt, water (100 mL) was added, the precipitate was collected by filtration and washed with cold Et 2 O (200 mL). The solid was redissolved in EtOAc (400 mL) and was washed with 1M aqueous NaOH solution (2 × 200 mL), saturated aqueous NaHCO 3 solution (200 mL), saturated aqueous NaCl solution (200 mL), dried (Na 2 
N-(6-Hydroxy-4-oxo-4H-chromen-2-yl)acetamide (16a)
Palladium on carbon (10%, 48 mg) was added to 15a (85 mg, 0.28 mmol) in 1:1 EtOAc:EtOH (17 mL) and the reaction was placed under an atmosphere of H 2 and stirred for 48 h at rt. The reaction was filtered through celite and the solvent was concentrated. 
N-(6-Hydroxy-4-oxo-4H-chromen-2-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (16b)
Palladium on carbon (10%, 531 mg) was added to 15b (499 mg, 0.98 mmol) in 3:1 EtOAc:EtOH (120 mL) and the reaction was placed under an atmosphere of H 2 and stirred for 18 h at rt. The reaction was filtered through celite and the solvent was concentrated. 
2-Acetamido-4-oxo-4H-chromen-6-yl acetate (17a)
4-(Dimethylamino)pyridine (28 mg, 0.23 mmol) and acetyl chloride (32 μL, 35 mg, 0.45 mmol) were sequentially added to 16a (31 mg, 0.14 mmol) in anhydrous acetonitrile (1.00 mL) and the solution was then heated to 80° C in a sealed flask for 18 h. After cooling to rt, the reaction was diluted with water (10 mL) and the solid was collected by filtration and washed with cold Et 2 O (20 mL) to give 17a as a light brown amorphous solid (27 mg -3-(3-methoxyphenyl)benzamido)-4-oxo-4H-chromen-6-yl acetate (17b) 4-(Dimethylamino)pyridine (33 mg, 0.27 mmol) and acetyl chloride (44 μL, 49 mg, 0.62 mmol) were sequentially added to 16b (27 mg, 0.06 mmol) in anhydrous acetonitrile (500 μL) and the solution was then heated to 80° C in a sealed flask for 18 h. After cooling to rt, the reaction was diluted with water (5 mL) and the solid was collected by filtration and washed with cold Et 2 O (10 mL) to give 17b as a brown amorphous solid (18 
2-(4-Methoxy
N-(6-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-4-oxo-4H-chromen-2-yl)acetamide (18a)
Boron trifluoride etherate (15 μL, 0.12 mmol) was added to 16a (49 mg, 0.23 mmol) and 
N-(6-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-4-oxo-4H-chromen-2-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (18b)
Boron trifluoride etherate (60 μL, 0.49 mmol) was added to 16b (101 mg, 0.24 mmol) and (3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH- 12 2-(1,3-Dioxoisoindolin-2-yl) acetonitrile (20) Aminoacetonitrile hydrochloride (5.00 g, 54.06 mmol), triethylamine (7.50 mL, 5.45 g, 53.81 mmol), and phthalic anhydride (8.00 g, 54.02 mmol) in chloroform (65 mL) were then heated to reflux for 18 h. After cooling to rt, the reaction was poured into water (65 mL) and the organic layer was washed with water (100 mL), saturated aqueous NaCl solution (100 mL), dried (Na 2 SO4), filtered, and concentrated to give 20 as a colorless amorphous solid (7.54 g, 75%): 1 H NMR (CDCl 3 , 500 MHz) δ 7.94 (m, 2H), 7.81 (m, 2H), 4.59 (s, 2H). 13 1-(2,4-Dihydroxyphenyl)-2-(2-isoindoline-1,3-dione) ethanone (22a) 15 mmol) and 20 (3.00 g, 16.12 mmol) in EtOAc (60 mL) was cooled to 0° C. After 15 min, zinc chloride (1.49 g, 10.95 mmol) was added, hydrochloric acid was bubbled through the solution for 10 min, and the reaction vessel was sealed and warmed to rt over 18 h. The reaction was filtered and the resulting solid was washed with cold EtOAc (3 × 50 mL) then added to water (25 mL) and then heated to reflux for 3 h. After cooling to rt, the solid was collected by filtration and washed with water (3 × 50 mL), then Et 2 O (3 × 100 mL) to give 22b as a yellow amorphous solid (3.39 Phloroglucinol (4.07 g, 32.29 mmol) and 20 (5.00 g, 26.86 mmol) in 1:1 Et 2 O:EtOAc (100 mL) was cooled to 0° C. After 15 min, zinc chloride (2.42 g, 17.78 mmol) was added, hydrochloric acid was bubbled through the solution for 10 min, and the reaction vessel was sealed and warmed to rt over 18 h. The reaction was filtered and the resulting solid was washed with cold EtOAc (3 × 50 mL) then added to water (150 mL) and then heated to reflux for 3 h.
5.
After Hydroxy-4-oxo-4H-chromen-3-yl)isoindoline-1,3-dione (23a) Boron trifluoride etherate (3.54 mL, 28.68 mmol) was added to 22a (1.32 g, 4.43 mmol) in anhydrous N,N-dimethylformamide (17.4 mL) at rt. After 10 min, methanesulfonyl chloride (1.44 mL, 2.13 g, 18.60 mmol) was added and the reaction was then heated to 90° C for 5 d. After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration. The solid was dissolved in EtOAc/MeOH (600 mL) and the organic layers were washed with water (400 mL), saturated aqueous NaCl solution (400 mL), dried (MgSO 4 /NaSO 4 ), filtered, and concentrated to give 23a as a brown amorphous solid (824 mg, 79%): 1 H NMR (DMSOd 6 , 500 MHz) δ 11.14 (brs, 1H), 8 
2-(7-
2-(7-Hydroxy-8-methyl-4-oxo-4H-chromen-3-yl)isoindoline-1,3-dione (23b)
Boron trifluoride etherate (5.00 mL, 40.51 mmol) was added to 22b (2.00 g, 6.43 mmol) in anhydrous N,N-dimethylformamide (24.8 mL) at rt. After 10 min, methanesulfonyl chloride (2.06 mL, 3.05 g, 26.62 mmol) was added and the reaction was then heated to 90° C for 5 d. After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration. The solid was dissolved in EtOAc/MeOH (600 mL) and the organic layers were washed with water (400 mL), saturated aqueous NaCl solution (400 mL), dried (MgSO 4 /NaSO 4 ), filtered, and concentrated to give 23b as a reddish-brown amorphous solid (1.72 g, 83%): 1 
2-(5,7-Dihydroxy-4-oxo-4H-chromen-3-yl)isoindoline-1,3-dione (23c)
Boron trifluoride etherate (10.8 mL, 87.51 mmol) was added to 22c (4.01 g, 12.81 mmol) in anhydrous N,N-dimethylformamide (53.2 mL) at rt. After 10 min, methanesulfonyl chloride (4.40 mL, 6.51 g, 56.85 mmol) was added and the reaction was then heated to 90° C for 2 d. After cooling to rt, water (600 mL) was added, the resulting solid was collected by filtration. The solid was dissolved in EtOAc/MeOH (800 mL) and the organic layers were washed with water (400 mL), saturated aqueous NaCl solution (400 mL), dried (MgSO 4 /NaSO 4 ), filtered, and concentrated to give 23c as a reddish-brown amorphous solid (4.12 g, 99%): 1 N-(7-Hydroxy-4-oxo-4H-chromen-3-yl)acetamide (24a) Compound 23a (192 mg, 0.62 mmol) in glacial acetic acid (2.0 mL) and concentrated hydrochloric acid (2.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted with water (10 mL) and the solvent was concentrated with heating. The resulting solid was concentrated from absolute EtOH (3 × 50 mL) and Et 2 O (100 mL) and used without further purification.
5.19
Acetyl chloride (150 μL, 166 mg, 2.11 mmol) was added to the crude aniline hydrochloride (146 mg, 0.47 mmol) in anhydrous acetonitrile (6.00 mL) and N,N-diisopropylethylamine (260 μL, 194 mg, 1.50 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with heating, the residue was dissolved in 3:1:1 THF:H 2 O:MeOH (50 mL), aqueous lithium hydroxide (3.0 M, 825 μL) was added, and the reaction stirred at rt. After 18 h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was purified via column chromatography (SiO 2 
N-(7-Hydroxy-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (24b)
Compound 23b (1.01 g, 3.14 mmol) in glacial acetic acid (10.0 mL) and concentrated hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted with water (50 mL) and the solvent was concentrated with heating. The resulting solid was concentrated from absolute EtOH (3 × 50 mL) and Et 2 O (100 mL) and used without further purification.
A solution of freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride 28 (830 mg, 3.00 mmol) in anhydrous acetonitrile (4.00 mL) was added to the crude aniline hydrochloride (1.57 mmol) in anhydrous acetonitrile (8.0 mL) and N,N-diisopropylethylamine (2.00 mL, 1.49 g, 11.53 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with heating, the residue was dissolved in 3:1:1 THF:H 2 O:MeOH (160 mL), aqueous lithium hydroxide (3.0 M, 2.75 mL) was added, and the reaction stirred at rt. After 18 h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was purified via column chromatography (SiO 2 
N-(7-Hydroxy-8-methyl-4-oxo-4H-chromen-3-yl)acetamide (24c)
Acetyl chloride (560 μL, 618 mg, 7.88 mmol) was added to the crude aniline hydrochloride (1.57 mmol) in anhydrous acetonitrile (12.00 mL) and N,N-diisopropylethylamine (2.00 mL, 1.49 g, 11.53 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with heating, the residue was dissolved in 3:1:1 THF:H 2 O:MeOH (160 mL), aqueous lithium hydroxide (3.0 M, 2.75 mL) was added, and the reaction stirred at rt. After 18 h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was purified via column chromatography (SiO 2 Hydroxy-8-methyl-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl) 
N-(7-
benzamide (24d)
Compound 23b (991 mg, 3.23 mmol) in glacial acetic acid (10.0 mL) and concentrated hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted with water (50 mL) and the solvent was concentrated with heating. The resulting solid was concentrated from absolute EtOH (3 × 50 mL) and Et 2 O (100 mL) and used without further purification.
A solution of freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride 28 (830 mg, 3.00 mmol) in anhydrous acetonitrile (4.00 mL) was added to the crude aniline hydrochloride (1.61 mmol) in anhydrous acetonitrile (8.0 mL) and N,N-diisopropylethylamine (500 μL, 373 mg, 2.88 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with heating, the residue was dissolved in 3:1:1 THF:H 2 O:MeOH (160 mL), aqueous lithium hydroxide (3.0 M, 2.75 mL) was added, and the reaction stirred at rt. After 5 h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was partially purified via column chromatography (SiO 2 , 3:1 Hexanes:EtOAc to 2:1 Hexanes:EtOAc to 2:1 EtOAc:Hexanes) and triturated with Et 2 O to provide solid that was used without further purificaiton.
Sodium hydroxide (161 mg, 4.03 mmol) was added to a solution of the solid (296 mg) in 1:1 MeOH:THF (15.0 mL). After 15 min, the solution was acidified to pH 1 with 6M aqueous HCl and the solvent was concentrated. The residue was triturated with Et 2 O and the resulting solid collected by filtration to give 24d as a yellow amorphous solid (87 mg, 14% over three steps): 1 H NMR (DMSO-d 6 , 500 MHz) δ 10.80 (brs, 1H), 9.41 (brs, 1H), 9.06 (s, 1H), 8 
N-(5,7-Dihydroxy-4-oxo-4H-chromen-3-yl)acetamide (24e)
Compound 23c (1.00 g, 3.11 mmol) in glacial acetic acid (10.0 mL) and concentrated hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted with water (50 mL) and the solvent was concentrated with heating. The resulting solid was concentrated from absolute EtOH (3 × 50 mL) and Et 2 O (100 mL) and used without further purification.
Acetyl chloride (1.20 mL, 1.32 g, 16.88 mmol) was added to the crude aniline hydrochloride (3.11 mmol) in anhydrous acetonitrile (24.0 mL) and N,N-diisopropylethylamine (3.00 mL, 2.24 g, 17.29 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with heating, the residue was dissolved in 3:1:1 THF:H 2 O:MeOH (320 mL), aqueous lithium hydroxide (3.0 M, 5.50 mL) was added, and the reaction stirred at rt. After 18 h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated, water (50 mL) was added, and the solid was collected by filtration and washed with cold Et 2 O (50 mL). 
N-(5,7-Dihydroxy-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxyphenyl)benzamide (24f)
Compound 23c (1.00 g, 3.10 mmol) in glacial acetic acid (10.0 mL) and concentrated hydrochloric acid (10.0 mL) was then heated to 100° C. After 5 h, the reaction was diluted with water (50 mL) and the solvent was concentrated with heating. The resulting solid was concentrated from absolute EtOH (3 × 50 mL) and Et 2 O (100 mL) and used without further purification.
A solution of freshly prepared 4-methoxy-3-(3-methoxyphenyl)benzoyl chloride 28 (1.77 g, 6.41 mmol) in anhydrous acetonitrile (8.00 mL) was added to the crude aniline hydrochloride (3.10 mmol) in anhydrous acetonitrile (16.00 mL) and N,N-diisopropylethylamine (6.00 mL, 4.47 g, 34.59 mmol) and the solution was stirred at rt. After 18 h, the solvent was concentrated with heating, the residue was dissolved in 3:1:1 THF:H 2 O:MeOH (160 mL), aqueous lithium hydroxide (3.0 M, 15.0 mL) was added, and the reaction stirred at rt. After 18 h, the reaction was acidified to pH 1 with 6M HCl, the solvent was concentrated and the residue was partially purified via column chromatography (SiO 2 , 1:1 Hexanes:EtOAc). Sodium hydroxide (161 mg, 4.03 mmol) was added to a solution of the residue in 1:1 MeOH:THF (15.0 mL). After 15 min, the solution was acidified to pH 1 with 6M aqueous HCl and the solvent was concentrated. 
3-Acetamido-4-oxo-4H-chromen-7-yl acetate (25a)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21 mmol) were added in sequence to 24a (13 mg, 0.06 mmol) in anhydrous acetonitrile (500 μL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (5 mL) and the precipitate was collected by filtration and washed with -3-(3-methoxyphenyl)benzamido)-4-oxo-4H-chromen-7-yl acetate (25b)   N,N-diisopropylethylamine (15 μL, 11 mg, 0 .09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21 mmol) were added in sequence to 24b (27 mg, 0.06 mmol) in anhydrous acetonitrile (500 μL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (5 mL) and the precipitate was collected by filtration and washed with cold 
3-(4-Methoxy
3-Acetamido-8-methyl-4-oxo-4H-chromen-7-yl acetate (25c)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21 mmol) were added in sequence to 24c (16 mg, 0.07 mmol) in anhydrous acetonitrile (500 μL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (5 mL) and the precipitate was collected by filtration and washed with cold 
3-(4-Methoxy-3-(3-methoxyphenyl)benzamido)-8-methyl-4-oxo-4H-chromen-7-yl acetate (25d)
N,N-diisopropylethylamine (15 μL, 11 mg, 0.09 mmol) and acetyl chloride (15 μL, 17 mg, 0.21 mmol) were added in sequence to 24d (18 mg, 0.04 mmol) in anhydrous acetonitrile (500 μL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (5 mL) and the precipitate was collected by filtration and washed with cold Et 2 O to give 25d as a colorless amorphous solid (17 Acetamido-5-hydroxy-4-oxo-4H-chromen-7-yl acetate (25e) N,N-diisopropylethylamine (17 μL, 13 mg, 0.10 mmol) and acetyl chloride (7 μL, 8 mg, 0.10 mmol) were added in sequence to 24e (22 mg, 0.07 mmol) in anhydrous acetonitrile (600 μL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (5 mL N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-4-oxo-4H-chromen-3-yl)-4-methoxy-3-(3-methoxylphenyl) 
3-
5.32
N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-4-oxo-4H-chromen-3-yl)acetamide (26c)
Boron trifluoride etherate (60 μL, 0.49 mmol) was added to 24c (52 mg, 0.22 mmol) and (3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c] pyran-4-yl 2,2,2-trichloroacetimidate (120 mg, 0.33 mmol) in anhydrous CH 2 Cl 2 (7.30 mL). After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated. The residue was partially purified via column chromatography (SiO 2 , 20:1 CH 2 Cl 2 :MeOH) and the coupled carbonate was used without further purification.
Carbonate was added to MeOH (4.0 mL), CH 2 Cl 2 (400 μL), and triethylamine (400 μL) and stirred for 18 h at rt. The solvent was concentrated and the residue purified via PTLC (SiO 2 , 10:1 CH 2 Cl 2 :MeOH then EtOAc) to give 26c as a colorless amorphous solid (7 mg After stirring at rt for 18 h, triethylamine (60 μL) was added and the solvent was concentrated. The residue was partially purified via column chromatography (SiO 2 , 1:1 Hexanes:EtOAc) and the coupled carbonate was used without further purification. 138.8, 131.2, 130.2, 129.4, 128.5, 125.8, 123.3, 122.2, 115.5, 113.3, 111.2, 105.5, 100.1, 97.8 [d][1,3]dioxol-5-yl)-1-(2,4-dihydroxyphenyl) ethanone (29a) 41 Resorcinol (2.21 g, 20.05 mmol) and 3,4-(methylenedioxy)phenylacetonitrile (3.12 g, 19.36 mmol) in EtOAc (60 mL) was cooled to 0° C. After 15 min, zinc chloride (1.47 g, 10.77 mmol) was added, hydrochloric acid was bubbled through the solution for 10 min, and the reaction vessel was sealed and warmed to rt over 18 h. The solvent was decanted away, water (25 mL) was added to the resulting oil, and the solution was then heated to reflux for 3 h. After cooling to rt, the solution was extracted with EtOAc (3 × 50 mL). The organic layers were dried (Na 2 SO 4 ), filtered, and concentrated. The residue was purified via column chromatography (SiO 2 , 2:1 Hexanes:EtOAc) to give 29a as a yellow amorphous solid (1. 41 2-Methylresorcinol (2.51 g, 20.19 mmol) and 3,4-(methylenedioxy)phenylacetonitrile (3.12 g, 19.37 mmol) in EtOAc (40 mL) was cooled to 0° C. After 15 min, zinc chloride (1.48 g, 10.89 mmol) was added, hydrochloric acid was bubbled through the solution for 10 min, and the reaction vessel was sealed and warmed to rt over 18 h. The solvent was decanted away, water (25 mL) was added to the resulting oil, and the solution was then heated to reflux for 3 h. After cooling to rt, the solution was extracted with EtOAc (3 × 50 mL). The organic layers were dried (Na 2 SO 4 ), filtered, and concentrated. Recrystallization from MeOH gave 29b as a yellow amorphous solid (1. 41 Boron trifluoride etherate (3.21 mL, 26.01 mmol) was added to 29a (1.11 g, 4.06 mmol) in anhydrous N,N-dimethylformamide (16.0 mL) at rt. After 10 min, methanesulfonyl chloride (1.31 mL, 1.94 g, 16.93 mmol) was added and the reaction was then heated to 90° C for 5 d. After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration to give 30a as a reddish-brown amorphous solid (1.08 g, 94%): 1 H NMR (DMSO- 41 Boron trifluoride etherate (3.35 mL, 27.14 mmol) was added to 29b (1.21 g, 4.24 mmol) in anhydrous N,N-dimethylformamide (16.5 mL) at rt. After 10 min, methanesulfonyl chloride (1.36 mL, 2.01 g, 17.57 mmol) was added and the reaction was then heated to 90° C for 5 d. After cooling to rt, water (300 mL) was added, the resulting solid was collected by filtration to give 30b as a reddish-brown amorphous solid (1. [d][1,3]dioxol-5-yl)-4-oxo-4H-chromen-7-yl acetate (31a) N,N-diisopropylethylamine (40 μL, 30 mg, 0.23 mmol) and acetyl chloride (40 μL, 44 mg, 0.56 mmol) were added in sequence to 30a (51 mg, 0.18 mmol) in anhydrous acetonitrile (1.30 mL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (5 mL) and the precipitate was collected by filtration. The residue was purified via column chromatography (SiO 2 , 2:1 Hexanes:EtOAc) to give 31a as a brown amorphous solid (26 31 (104 mg, 0.35 mmol) in anhydrous acetonitrile (2.50 mL) and the solution was then heated to reflux for 5 min and cooled to rt. After 18 h, the reaction was diluted with water (10 mL), the precipitate was collected by filtration and washed with cold Et 2 O (3 × 10 mL). The residue was purified via column chromatography (SiO 2 Boron trifluoride etherate (88 μL, 0.71 mmol) was added to 30a (102 mg, 0.36 mmol) and (3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c] pyran-4-yl 2,2,2-trichloroacetimidate (134 mg, 0.37 mmol) in anhydrous CH 2 Cl 2 (11.60 mL). After stirring at rt for 18 h, triethylamine (100 μL) was added and the solvent was concentrated.
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per the manufacturer's instructions. Equal amounts of protein (20 μg) were electrophoresed under reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with the corresponding specific antibodies. Membranes were incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and visualized.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Structures of novobiocin, A4, and A4-dimer. Structure of derrubone. Proposed overlay of novobiocin analogues (eg. 3) and 2 that were used to prepare flavone and isoflavone chimeras (4). Novobiocin-derrubone chimeric analogues. Western blot analysis of Hsp90 and Hsp90 client proteins against MCF-7 breast cancer cells. Concentrations (in μM) of 26b (top) and 37c (bottom) are indicated above each lane. GDA (geldanamycin, 500 nM) and DMSO were respectively employed as positive and negative controls. Summary of structure-activity trends for chimeric analogues of novobiocin and derrubone. 
